Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Sigma-Tau reports identification of novel HSP90 inhibitors

Feb. 26, 2010

HSP90 inhibitor STA-9090 targets oncogenic functions of Wilms tumor protein in AML cells

Feb. 25, 2010

Enzon treats first pediatric cancer patient in phase I PEG-SN38 trial

Feb. 25, 2010

Phase III NOV-002 trial in NSCLC fails to meet primary endpoint

Feb. 25, 2010

Hutchison MediPharma presents novel epidermal growth factor receptor inhibitors

Feb. 25, 2010

Novel focal adhesion kinase inhibitors discovered at AstraZeneca

Feb. 25, 2010

European CHMP issues two positive opinions for GSK's Tyverb and Votrient in cancer

Feb. 24, 2010

EMA recommends orphan drug status for Aprea's APR-246 for AML

Feb. 24, 2010

Merrimack begins phase I/II trial of MM-121/Tarceva in NSCLC

Feb. 24, 2010

Roche reports on global phase III Avastin trial in stomach cancer

Feb. 24, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...